Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Hepatocellular 8Stomach Neoplasms 5Triple Negative Breast Neoplasms 3Liver Neoplasms 3Breast Neoplasms 3Small Cell Lung Carcinoma 2Nasopharyngeal Carcinoma 2Gastrointestinal Stromal Tumors 2Esophageal Squamous Cell Carcinoma 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Adrenocortical Carcinoma 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Cancer Limited Stage 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Salivary Gland Neoplasms 1SCLC 1Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Meningioma 1Melanoma 1Malignant Neoplasms of Digestive Organs 1Locally Advanced Thyroid Gland Carcinoma 1Immunotherapy Gastrict Cancer 1HER2-negative Breast Cancer Brain Metastases 1Gestational Trophoblastic Disease 1

Interventions

olaparib 1lutetium Lu 177 dotatate 1camrelizumab 1apatinib 1Nivolumab 1Mitotane 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Floxuridine 1FAPI-46 1Dexamethasone 1Adrenalectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Adrenal Gland Neoplasms × apatinib × Clear all
NCT06831175 2025-06-03

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

West China Hospital

Phase 2 Recruiting
28 enrolled
Endocrine

Adrenal Gland Neoplasms, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡